CSNK1A1 and breast cancer: In CRC, Pyrvinium reduces Wnt-driven biomarker levels and inhibits adenoma formation in APCmin mice, a model for CRC.703–705 Additionally, in OC, Pyrvinium increases the sensitivity of cancer cells to chemotherapy, and in BC, it inhibits the self-renewal and metastasis of CSCs.706,707 Another CK1α activator, SSTC3, has also demonstrated tumor-suppressive effects in both CRC and medulloblastoma, suggesting the therapeutic potential of CK1α agonists in various cancers driven by Wnt signaling.708,709